C. Pettinelli

发表

A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.

T. Merigan, J. Kahn, S. Lagakos, 1992, The New England journal of medicine.

Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection

S W Lagakos, M. Hirsch, T. Merigan, 1990 .

The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection a double-blind, placebo-controlled trial

Douglas D. Richman, William G. Powderly, F. S. Rhame, 1990 .

Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. An AIDS Clinical Trials Group Study.

C. Pettinelli, S. Spector, D. Dieterich, 1990, Annals of internal medicine.

A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.

M. Wulfsohn, M. Hirsch, C. Parker, 1990, The New England journal of medicine.

2',3'-Dideoxyinosine in patients with AIDS or AIDS-related complex.

C. Pettinelli, J. Lambert, R. Reichman, 1990, Reviews of infectious diseases.

Encephalitogenic activity of guinea pig myelin basic protein in the SJL mouse.

C. Pettinelli, D. McFarlin, C. Chou, 1982, Journal of immunology.

An open-label, dose-ranging trial of AL 721 in patients with persistent generalized lymphadenopathy and AIDS-related complex.

C. Pettinelli, H. Sacks, F. Rhame, 1991, Journal of acquired immune deficiency syndromes.

The Concorde trial

S. Lagakos, C. Pettinelli, P. Volberding, 1993, The Lancet.

2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial.

C. Pettinelli, J. Lambert, R. Reichman, 1990, The New England journal of medicine.

Antiretroviral Therapy for Adult HIV-lnfected Patients: Recommendations From a State-of-the-Art Conference

R. Schooley, J. Phair, M. Hirsch, 1993 .

A pilot study of low-dose zidovudine in human immunodeficiency virus infection.

D. Richman, C. Pettinelli, S. Spector, 1990, The New England journal of medicine.

Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS.

C. Pettinelli, J. Hodges, M. Loveless, 1996, The New England journal of medicine.

Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.

Victor De Gruttola, Robert W Shafer, Stefano Vella, 2003, The New England journal of medicine.

A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome

M. Wulfsohn, M. Hirsch, T. Merigan, 1990 .

Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators.

C. Pettinelli, I. Marschner, V. Johnson, 1999, AIDS.

Zidovudine Compared With Didanosine in Patients With Advanced HIV Type I Infection and Little or No Previous Experience With Zidovudine

K. K. Lai, D. Katzenstein, M. Hirsch, 1995 .

H-2-linked genetic control of murine T-cell-mediated lympholysis to autologous cells modified with low concentrations of trinitrobenzene sulfonate

C. Pettinelli, M. Miller, G. Shearer, 1979, The Journal of experimental medicine.

Statistical issues for HIV surrogate endpoints: point/counterpoint. An NIAID workshop.

J M Taylor, L A Kalish, J. Ioannidis, 1998, Statistics in medicine.

Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1+ 2- T lymphocytes.

C. Pettinelli, D. McFarlin, D E McFarlin, 1981, Journal of immunology.

Cell types required for H-2-restricted cytotoxic responses generated by trinitrobenzene sulfonate-modified syngeneic cells or trinitrophenyl-conjugated proteins.

C. Pettinelli, G. Shearer, A. Schmitt-Verhulst, 1979, Journal of immunology.

Comparison of Two Indinavir/Ritonavir Regimens in the Treatment of HIV-Infected Individuals

Hulin Wu, Song Yu, Edward P Acosta, 2004, Journal of acquired immune deficiency syndromes.

Toxic effects of zidovudine in asymptomatic human immunodeficiency virus-infected individuals with CD4+ cell counts of 0.50 x 10(9)/L or less. Detailed and updated results from protocol 019 of the AIDS Clinical Trials Group.

S. Lagakos, C. Pettinelli, P. Volberding, 1992, Archives of Internal Medicine.

Safety and Efficacy of zidovudine in asymptomatic HIV infected individuals withless than 500 CD4+ cells/mm3.

S. Lagakos, D. Richman, C. Pettinelli, 1990 .

Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials Group.

M. Hirsch, A. Cross, C. Pettinelli, 1995, Archives of internal medicine.

NIAID Workshop, Memphis, Tennessee, 25-26 March 1997: Statistical issues for HIV surrogate endpoints: Point/counterpoint

John P. A. Ioannidis, Michael Hughes, Jeffrey M. Albert, 1998 .

Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: ACTG 068

C. Pettinelli, H. Sacks, M. Fischl, 1996 .

Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: AIDS Clincal Trial Group 068.

C. Pettinelli, H. Sacks, M. Fischl, 1996, Antiviral therapy.

Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370

C. Pettinelli, I. Marschner, V. Johnson, 2000, AIDS.

Expression of both I-A and I-E/C subregion antigens on accessory cells required for in vitro generation of cytotoxic T lymphocytes against alloantigens or TNBS-modified syngeneic cells.

C. Pettinelli, G. Shearer, G. B. Ahmann, 1980, Journal of immunology.